RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

Description

Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy

Conditions

Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology

Study Overview

Study Details

Study overview

Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy

Randomized Controlled Trial of Olanzapine for the Control of Chemotherapy-induced Vomiting in Children Receiving Highly Emetogenic Chemotherapy

RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

Condition
Vomiting in Infants and/or Children
Intervention / Treatment

-

Contacts and Locations

San Francisco

University of California, San Francisco, California, United States, 94158

Kansas City

The Children's Mercy Hospital, Kansas City, Missouri, United States, 64108

New York

Columbia University/Morgan Stanley Children's Hospital, New York, New York, United States, 10032

Chapel Hill

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States, 27599-7220

Columbus

Nationwide Children's Hospital, Columbus, Ohio, United States, 43205

Charleston

Medical University of South Carolina, Charleston, South Carolina, United States, 29425

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    30 Months to 18 Years

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    The Hospital for Sick Children,

    Lee Dupuis, RPh, PhD, PRINCIPAL_INVESTIGATOR, The Hospital for Sick Children

    Muhammad Ali, MD, PRINCIPAL_INVESTIGATOR, The Hospital for Sick Children

    Study Record Dates

    2025-04